Skip to content
Subscriber Only
Opinion
Max Nisen

Biotech's IPO Uptick Is Nothing to Fear

Unlike 2015, the market is recovering, but not frothy.
A TV cameraman shoots video through the windows of the Nasdaq offices in Times Square on June 24, 2016 in New York.

A TV cameraman shoots video through the windows of the Nasdaq offices in Times Square on June 24, 2016 in New York.

The biotech IPO market is unusual.

It can take a decade to develop a drug, so these companies demand long leashes and heroic tolerance for losses. Instead of valuing a business, IPO investors often must value a medicine or idea years away from the market. Given all the guesswork and risk involved, sentiment plays an outsize role in the ability of biotechs to go public.